BIOPOR Bioporto A/S

Peter Mørch Eriksen resigns as CEO of BioPorto A/S

Peter Mørch Eriksen resigns as CEO of BioPorto A/S

May 5, 2021

Announcement no. 10

Peter Mørch Eriksen resigns as CEO of BioPorto A/S

After having led BioPorto as CEO for almost 8 years, BioPorto’s Chief Executive Officer, is resigning his position as CEO of the Company. Peter will continue to support the Company until end of January 2022, and will retain his position as CEO until his successor has been found.

Peter Mørch Eriksen says: “It is, and has been, a privilege to be CEO of BioPorto, and I look forward to continue to support the Company’s ongoing projects, including the clinical studies and expected submission this summer of a De Novo application to the FDA for pediatric use of The NGAL Test™. Considering the important milestones ahead for BioPorto, I find this to be the right time to find my successor who can lead the Company into its next phase.”

Thomas Magnussen, Chairman of the Board of Directors, says: “I wish to thank Peter for his tremendous efforts for the Company over many years. I and the rest of the organization look forward to continue working with Peter over the coming months, as we proceed to identify and appoint his successor and further advance the ongoing transition of the Company to the North American market.”

For further information, please contact:

Thomas Magnussen, Chairman of the Board

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment



EN
05/05/2021

Underlying

BIOPORBioporto A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto attends the Association for Diagnostics & Laboratory Medicine...

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. July 28, 2025News Release BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. Laboratory medicine continues to focus on kidney diagnostics. BioPorto is pleased to announce its attendance and the general multiple NGAL and Acute Kidney Injury (AKI) focused elements of the Association for Diagnostics Medicine meeting, this year held in...

July 28, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Påbegyndelse af kommercialisering af ProNephro AKI (NGAL) til diagnost...

Påbegyndelse af kommercialisering af ProNephro AKI (NGAL) til diagnostisk brug i USA 27. juni, 2025Meddelelse nr. 18 Påbegyndelse af kommercialisering af ProNephro AKITM (NGAL) til diagnostisk brug i USA KØBENHAVN, DANMARK og BOSTON, MA, USA, 27. juni 2025 – BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) meddelte i dag, at de har påbegyndt kommercialisering i USA af ProNephro AKITM (NGAL) til klinisk anvendelse i risikostratificering af moderat til svær AKI for patienter i alderen 3 måneder til 21 år, ved at modtage den første købsordre på ProNephro AKITM (NGAL) til det amerik...

June 27, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic...

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US June 27, 2025Announcement no. 18 Initiation of commercialization of ProNephro AKITM (NGAL) for diagnostic use in the US COPENHAGEN, DENMARK and BOSTON, MA, USA, June 27, 2025 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) today announced the initiation of commercialization in the US of ProNephro AKITM (NGAL) for clinical use in risk stratification for moderate-to-severe AKI for patients aged 3 months to 21 years, by receiving the first purchase order of ProNephro AKITM (NGAL) for the US market...

June 27, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Tildeling af Warrants

Tildeling af Warrants 12. juni 2025Meddelelse nr. 17                                                                          Tildeling af Warrants København, Danmark, den 12. juni 2025 (GLOBE NEWSWIRE) – Bestyrelsen for BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) har i dag besluttet at udstede i alt 3.250.000 warrants til Selskabets Extended Leadership Team. Hver warrant giver indehaveren ret til at tegne én aktie i BioPorto til en udnyttelseskurs på 1,39 kr. pr. aktie, svarende til lukkekursen på Nasdaq Copenhagen i dag. Warrants udstedes i henhold til § 18 a i Selskabets...

June 12, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Grant of Warrants

Grant of Warrants 12 June 2025 Announcement no. 17                                                                          Grant of Warrants Copenhagen, Denmark, June 12, 2025, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today decided to issue a total of 3,250,000 warrants to the Extended Leadership Team. Each warrant entitles the holder the right to subscribe for one share in BioPorto at an exercise price of DKK 1.39 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are issued in accord...

June 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch